biostudies-literatureUnknownSierra MSNational Institutes of Health Office of Research on Women’s HealthWorld Health OrganizationNational Cancer InstituteNCI NIH HHS<h4>Introduction</h4>Human papillomavirus (HPV) vaccines protect against incident HPV infections, which cause cervical cancer.<h4>Objectives</h4>We estimated the prevalence and incidence of HPV infections in young adult women to understand the impact of an HPV vaccination programme in this population.<h4>Methods</h4>We collected cervical specimens from 6322 unvaccinated women, aged 18-37 years, who participated in the Costa Rica Vaccine Trial and its long-term follow-up. Women were followed for (median) 4.8 years and had (median) 4.0 study visits. Cervical specimens were tested for the presence/absence of 25 HPV genotypes. For each age band, we estimated the percentage of women with 1+ prevalent or 1+ incident HPV infections using generalised estimating equations. We also estimated the preSexually transmitted infectionssextrans-2022-055434https://www.ebi.ac.uk/biostudies/studies/S-EPMC10176398biostudies-literatureAnalysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial.PMC10176398001N01 CP011005N01-CP-11005Sampson JNHu SCortes BRodriguez ACSchussler JStoler MHSidawy MKStruijk LLowy DRGonzalez PSherman MWacholder SCarvajal LJimenez SEQuint WKemp TJPorras CSchiffman MCosta Rica HPV Vaccine Trial (CVT) GroupKreimer ARSierra MSTsang SHSchiller JTDarragh TMPalefsky JMRomero BWagner SPinto LAvan Doorn LJHerrero RHildesheim AfalseAnalysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial.<h4>Introduction</h4>Human papillomavirus (HPV) vaccines protect against incident HPV infections, which cause cervical cancer.<h4>Objectives</h4>We estimated the prevalence and incidence of HPV infections in young adult women to understand the impact of an HPV vaccination programme in this population.<h4>Methods</h4>We collected cervical specimens from 6322 unvaccinated women, aged 18-37 years, who participated in the Costa Rica Vaccine Trial and its long-term follow-up. Women were followed for (median) 4.8 years and had (median) 4.0 study visits. Cervical specimens were tested for the presence/absence of 25 HPV genotypes. For each age band, we estimated the percentage of women with 1+ prevalent or 1+ incident HPV infections using generalised estimating equations. We also estimated the pre2022-01-01T00:00:00Z2022 Jul2026-06-14T07:48:41.64Z2025-04-04T11:50:41.352ZS-EPMC101763983584222910.1136/sextrans-2022-055434